Glenn Sblendorio Iveric Bio, Inc. (ISEE) insider trading activity

Glenn Sblendorio is Chief Executive Officer of IVERIC bio, Inc.. Currently has a direct ownership of 0 shares of ISEE, which is worth approximately $0. The most recent transaction as insider was on Jul 11, 2023, when has been sold 239,275 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

GLENN SBLENDORIO Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 11 2023	SELL Sale (or disposition) back to the issuer	-	239,275 Reduced 100.0%	0 Common Stock
Jun 22 2023	BUY Exercise of conversion of derivative security	$146,530 $13.22 p/Share	11,084 Added 4.43%	239,275 Common Stock
Jan 03 2023	SELL Open market or private sale	$349,986 $20.06 p/Share	17,447 Reduced 7.1%	228,191 Common Stock
Jan 02 2023	BUY Exercise of conversion of derivative security	-	31,500 Added 11.37%	245,638 Common Stock
Dec 27 2022	SELL Bona fide gift	-	30,000 Reduced 12.29%	214,138 Common Stock
Dec 19 2022	SELL Open market or private sale	$418,520 $21.51 p/Share	19,457 Reduced 7.38%	244,138 Common Stock
Dec 18 2022	BUY Exercise of conversion of derivative security	-	36,658 Added 12.21%	263,595 Common Stock
Dec 12 2022	BUY Exercise of conversion of derivative security	-	22,950 Added 9.18%	226,937 Common Stock
Dec 09 2022	BUY Exercise of conversion of derivative security	-	23,750 Added 10.43%	203,987 Common Stock
Nov 02 2022	SELL Open market or private sale	$1,150,500 $23.01 p/Share	50,000 Reduced 21.77%	179,689 Common Stock
Apr 04 2022	SELL Open market or private sale	$938,000 $18.76 p/Share	50,000 Reduced 17.88%	229,689 Common Stock
Apr 01 2022	SELL Open market or private sale	$713,230 $17.5 p/Share	40,756 Reduced 12.72%	279,689 Common Stock
Apr 01 2022	BUY Exercise of conversion of derivative security	$119,823 $2.94 p/Share	40,756 Added 11.28%	320,445 Common Stock
Mar 31 2022	SELL Open market or private sale	$23,828 $17.02 p/Share	1,400 Reduced 0.5%	279,689 Common Stock
Mar 31 2022	BUY Exercise of conversion of derivative security	$4,116 $2.94 p/Share	1,400 Added 0.5%	281,089 Common Stock
Mar 30 2022	SELL Open market or private sale	$20,621 $17.0 p/Share	1,213 Reduced 0.43%	279,689 Common Stock
Mar 30 2022	BUY Exercise of conversion of derivative security	$3,566 $2.94 p/Share	1,213 Added 0.43%	280,902 Common Stock
Mar 25 2022	SELL Open market or private sale	$320,301 $17.06 p/Share	18,775 Reduced 6.29%	279,689 Common Stock
Mar 25 2022	BUY Exercise of conversion of derivative security	$55,199 $2.94 p/Share	18,775 Added 5.92%	298,464 Common Stock
Mar 18 2022	SELL Open market or private sale	$59,143 $17.0 p/Share	3,479 Reduced 1.23%	279,689 Common Stock
Mar 18 2022	BUY Exercise of conversion of derivative security	$10,228 $2.94 p/Share	3,479 Added 1.21%	283,168 Common Stock
Dec 31 2021	SELL Open market or private sale	$13,617 $17.0 p/Share	801 Reduced 0.29%	279,133 Common Stock
Dec 31 2021	BUY Exercise of conversion of derivative security	$2,355 $2.94 p/Share	801 Added 0.29%	279,934 Common Stock
Dec 30 2021	SELL Open market or private sale	$1,701 $17.01 p/Share	100 Reduced 0.04%	279,133 Common Stock
Dec 30 2021	BUY Exercise of conversion of derivative security	$294 $2.94 p/Share	100 Added 0.04%	279,233 Common Stock

Also insider at

ICPT

INTERCEPT PHARMACEUTICALS, INC. Healthcare

Director

FOLD

AMICUS THERAPEUTICS, INC. Healthcare

MLYS

Mineralys Therapeutics, Inc.

Director